FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982170248> ?p ?o ?g. }

• W1982170248 endingPage "159" @default.
• W1982170248 startingPage "154" @default.
• W1982170248 abstract "Tenecteplase (TNK) was engineered to have increased fibrin specificity and an increased half-life compared to Alteplase. Although Tenecteplase is currently being tested in a Phase II clinical trial in acute ischemic stroke patients, little is known about the pharmacology and dose-response or therapeutic window for Tenecteplase in embolic stroke models. In the present study, we compared Tenecteplase with Alteplase on behavioral outcome in rabbits with embolic strokes. Male New Zealand white rabbits were embolized by injecting a suspension of small blood clots into the middle cerebral artery (MCA) via a catheter. The rabbit small clot embolic stroke model (RSCEM) was used for a dose-response profile analysis of Tenecteplase (0.1 mg/kg-3.3 mg/kg) and Alteplase (0.9 mg/kg-3.3 mg/kg) given intravenously 1 h following embolization. In additional studies, Tenecteplase (0.9 mg/kg) or Alteplase (3.3 mg/kg) was administered 3 (or 6) h following embolization to determine the therapeutic window for the thrombolytics. For both studies, behavioral analysis was conducted 24 h following embolization, allowing for the determination of the effective stroke dose (P50) or clot amount (mg) that produces neurological deficits in 50% of the rabbits. Using the RSCEM, a drug is considered beneficial if it significantly increases the P50 compared with the control group. The P50 of controls 24 h after embolization was 1.13 +/- 0.15 mg. Rabbits treated 1 h post-embolization with Tenecteplase (0.1, 0.25, 0.9, 1.5 or 3.3 mg/kg) had P50 values of 1.48 +/- 0.33, 2.20 +/- 0.44, 2.76 +/- 0.37, 2.15 +/- 0.29 and 2.78 +/- 0.31 mg, respectively. In Alteplase-treated rabbits, only the 3.3 mg/kg dose significantly increased the group P50 by 189% compared to control. Tenecteplase was also effective at increasing the P50 value to 2.21 +/- 0.43 mg if there was a 3-h delay following embolization, but not if there was a 6-h delay before administration. Alteplase was only effective if administered 1 h following embolization where it significantly increased the P50 value to 3.27 +/- 0.40 mg. This study indicates that Tenecteplase has a wide therapeutic range, a therapeutic window of at least 3 h and a durable effect. Moreover, the safety profile for Tenecteplase is similar to that of Alteplase. Tenecteplase does not increase the rate of intracerebral hemorrhage (ICH) above that produced by Alteplase. However, the therapeutic range and window for Alteplase is more limited than that for Tenecteplase. Our preclinical studies suggest that Tenecteplase has a better pharmacological profile than Alteplase and supports further investigation of Tenecteplase in randomized double-blinded clinical trials in stroke patients." @default.
• W1982170248 created "2016-06-24" @default.
• W1982170248 creator A5016280147 @default.
• W1982170248 creator A5028934169 @default.
• W1982170248 creator A5060081589 @default.
• W1982170248 date "2004-01-01" @default.
• W1982170248 modified "2023-10-10" @default.
• W1982170248 title "Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits" @default.
• W1982170248 cites W1965075754 @default.
• W1982170248 cites W1972581867 @default.
• W1982170248 cites W1976299524 @default.
• W1982170248 cites W1979961027 @default.
• W1982170248 cites W1991906540 @default.
• W1982170248 cites W1995762191 @default.
• W1982170248 cites W1999328892 @default.
• W1982170248 cites W2006004617 @default.
• W1982170248 cites W2009436292 @default.
• W1982170248 cites W2029700290 @default.
• W1982170248 cites W2030026141 @default.
• W1982170248 cites W2033911057 @default.
• W1982170248 cites W2043337210 @default.
• W1982170248 cites W2061574455 @default.
• W1982170248 cites W2081209497 @default.
• W1982170248 cites W2088115137 @default.
• W1982170248 cites W2096265281 @default.
• W1982170248 cites W2104627430 @default.
• W1982170248 cites W2122765865 @default.
• W1982170248 cites W2123648780 @default.
• W1982170248 cites W2129598039 @default.
• W1982170248 cites W2134164486 @default.
• W1982170248 cites W2144859488 @default.
• W1982170248 cites W2159906177 @default.
• W1982170248 cites W2169510138 @default.
• W1982170248 cites W2171428594 @default.
• W1982170248 cites W2292308933 @default.
• W1982170248 cites W4211255027 @default.
• W1982170248 doi "https://doi.org/10.1016/j.expneurol.2003.09.009" @default.
• W1982170248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14697326" @default.
• W1982170248 hasPublicationYear "2004" @default.
• W1982170248 type Work @default.
• W1982170248 sameAs 1982170248 @default.
• W1982170248 citedByCount "64" @default.
• W1982170248 countsByYear W19821702482012 @default.
• W1982170248 countsByYear W19821702482013 @default.
• W1982170248 countsByYear W19821702482014 @default.
• W1982170248 countsByYear W19821702482015 @default.
• W1982170248 countsByYear W19821702482016 @default.
• W1982170248 countsByYear W19821702482017 @default.
• W1982170248 countsByYear W19821702482019 @default.
• W1982170248 countsByYear W19821702482021 @default.
• W1982170248 countsByYear W19821702482022 @default.
• W1982170248 countsByYear W19821702482023 @default.
• W1982170248 crossrefType "journal-article" @default.
• W1982170248 hasAuthorship W1982170248A5016280147 @default.
• W1982170248 hasAuthorship W1982170248A5028934169 @default.
• W1982170248 hasAuthorship W1982170248A5060081589 @default.
• W1982170248 hasConcept C126322002 @default.
• W1982170248 hasConcept C127413603 @default.
• W1982170248 hasConcept C141071460 @default.
• W1982170248 hasConcept C164705383 @default.
• W1982170248 hasConcept C2775841333 @default.
• W1982170248 hasConcept C2776035437 @default.
• W1982170248 hasConcept C2776572282 @default.
• W1982170248 hasConcept C2777377995 @default.
• W1982170248 hasConcept C2779095551 @default.
• W1982170248 hasConcept C2779581417 @default.
• W1982170248 hasConcept C2780645631 @default.
• W1982170248 hasConcept C2909817843 @default.
• W1982170248 hasConcept C42219234 @default.
• W1982170248 hasConcept C500558357 @default.
• W1982170248 hasConcept C541997718 @default.
• W1982170248 hasConcept C71924100 @default.
• W1982170248 hasConcept C78519656 @default.
• W1982170248 hasConceptScore W1982170248C126322002 @default.
• W1982170248 hasConceptScore W1982170248C127413603 @default.
• W1982170248 hasConceptScore W1982170248C141071460 @default.
• W1982170248 hasConceptScore W1982170248C164705383 @default.
• W1982170248 hasConceptScore W1982170248C2775841333 @default.
• W1982170248 hasConceptScore W1982170248C2776035437 @default.
• W1982170248 hasConceptScore W1982170248C2776572282 @default.
• W1982170248 hasConceptScore W1982170248C2777377995 @default.
• W1982170248 hasConceptScore W1982170248C2779095551 @default.
• W1982170248 hasConceptScore W1982170248C2779581417 @default.
• W1982170248 hasConceptScore W1982170248C2780645631 @default.
• W1982170248 hasConceptScore W1982170248C2909817843 @default.
• W1982170248 hasConceptScore W1982170248C42219234 @default.
• W1982170248 hasConceptScore W1982170248C500558357 @default.
• W1982170248 hasConceptScore W1982170248C541997718 @default.
• W1982170248 hasConceptScore W1982170248C71924100 @default.
• W1982170248 hasConceptScore W1982170248C78519656 @default.
• W1982170248 hasIssue "1" @default.
• W1982170248 hasLocation W19821702481 @default.
• W1982170248 hasLocation W19821702482 @default.
• W1982170248 hasOpenAccess W1982170248 @default.
• W1982170248 hasPrimaryLocation W19821702481 @default.
• W1982170248 hasRelatedWork W2044898829 @default.
• W1982170248 hasRelatedWork W2161755146 @default.
• W1982170248 hasRelatedWork W2500172526 @default.

• next